Neuland Laboratories
From Wikipedia, the free encyclopedia
| NSE: NEULANDLAB BSE : 524558 | |
| Company type | Public |
| Industry | CDMO |
| Founded | January 7 1984 |
| Headquarters | , |
Area served | North America, Switzerland, UK, Germany, Italy and the Netherlands and 80 more countries. |
Key people | Dr. Davuluri Rama Mohan Rao (Executive Chairman) D. Sucheth Rao (Executive Vice Chairman) D. Saharsh Rao (Chief Executive Officer & Managing Director) |
Number of employees | ~2,000 (including 360+ scientists) [1] |
| Website | www |
Neuland Laboratories Limited is an Indian publicly listed contract development and manufacturing organization (CDMO) headquartered in Hyderabad.[2] Founded in 1984, the company produces active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs.[3] Its shares are traded on the Bombay Stock Exchange and the National Stock Exchange.[4][5]
Neuland operates through two primary business verticals: Generic Drug Substances (GDS) and CDMO services. Its operations span process research and development, custom synthesis, scale-up, regulatory documentation support, and commercial manufacturing.[6]
The company exports products to more than 80 countries and maintains approvals from major international regulatory authorities, including the United States Food and Drug Administration (US FDA), European Directorate for the Quality of Medicines (EDQM), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).[7]
As of 2025, Neuland employs approximately 2,000 people, including over 360 scientists engaged in research and development activities.[8]
Product development
The company's operations are divided into three segments: Custom Manufacturing Solutions, which develops APIs from pre-clinical to commercial stages; Generic Drug Substances, which manufactures non-exclusive APIs; and a Peptide API unit that specializes in peptide synthesis.[9]